Gavin Tsuchida, DPM
Podiatrist · Torrance, CANPI 1902394083
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,400 of the $3,820 with a category attached, or 62.8%. Elevate Surgical Co accounts for 65.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $2,655 and has fallen 86.8% since, to $349 in 2025.
Across 54 payments — averaging $70.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elevate Surgical Co$2K
- Arthrex$213
- Biotissue Holdings Inc.$179
- Paratek Pharmaceuticals, Inc.$132
- Smith+Nephew$88
- Bioventus LLC$77
- plus $651 from 19 others
What the payments were for
- Food & beverage$1,42037%
- Education$2,40063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elevate Surgical Co | 4 | $2,481 |
| Arthrex | 4 | $213 |
| Biotissue Holdings Inc. | 3 | $179 |
| Paratek Pharmaceuticals, Inc. | 7 | $132 |
| Smith+Nephew | 5 | $88 |
| Bioventus LLC | 3 | $77 |
| DJO, LLC | 2 | $72 |
| Treace Medical Concepts, Inc. | 1 | $50 |
| Vertex | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| Johnson & Johnson | 1 | $44 |
| Solventum Corporation | 2 | $44 |
| Acera Surgical, Inc. | 2 | $37 |
| Saxum Surgical, Inc. | 1 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Integra Lifesciences Corporation | 2 | $33 |
| Nevro Corp. | 2 | $31 |
| AbbVie | 2 | $29 |
| Mimedx Group, Inc. | 1 | $29 |
| Organogenesis Inc. | 1 | $28 |
| Stryker | 1 | $26 |
| BD | 1 | $24 |
| Kerecis Limited | 1 | $21 |
| Urgo Medical North America, LLC | 1 | $15 |
| Reprise Biomedical, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,820 in reported general payments places this provider in the 80th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 132 | $2,341 |
| Clotrimazole | 30 | $761 |
| Diclofenac Sodium | 33 | $646 |
| Ammonium Lactate | 17 | $325 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $214 |
| Cephalexin | 12 | $170 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $112 |
| Meloxicam | 19 | $15 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Torrance
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.